| __timestamp | BioCryst Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 504755000 |
| Thursday, January 1, 2015 | 13047000 | 838526000 |
| Friday, January 1, 2016 | 11253000 | 1177697000 |
| Sunday, January 1, 2017 | 13933000 | 1320433000 |
| Monday, January 1, 2018 | 29514000 | 1556200000 |
| Tuesday, January 1, 2019 | 37121000 | 1834800000 |
| Wednesday, January 1, 2020 | 67929000 | 1346000000 |
| Friday, January 1, 2021 | 118818000 | 1824900000 |
| Saturday, January 1, 2022 | 159371000 | 2115900000 |
| Sunday, January 1, 2023 | 213894000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Regeneron, a leader in the field, has consistently outpaced BioCryst, with its SG&A expenses growing from approximately $500 million in 2014 to over $2.6 billion in 2023, marking a staggering 420% increase. In contrast, BioCryst's SG&A expenses rose from about $7 million to $214 million, reflecting a 2800% surge. This disparity highlights Regeneron's robust market position and aggressive expansion strategies, while BioCryst's growth underscores its evolving presence in the biotech sector. These trends offer valuable insights into the strategic priorities and market dynamics of these industry players.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. vs Jazz Pharmaceuticals plc: SG&A Expense Trends
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.